Osimertinib combo for advanced lung cancer with EGFR mutation
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination treatment for people with advanced non-small cell lung cancer that has an EGFR mutation and shows PD-L1 protein. It may help if previous treatments have stopped working or as a first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have non-small cell lung cancer with an EGFR mutation and PD-L1 expression.
- Your cancer must be locally advanced or metastatic (spread).
- For the dose-escalation group: you must have had at least two prior treatments, including a third-generation EGFR inhibitor like osimertinib.
- For the expansion group: you must not have had any prior systemic therapy for advanced disease.
- You must have at least one measurable tumor and be in good physical condition (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
Hear when a new Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.